Interferon alfa ( DrugBank: Interferon alfa )


5 diseases
IDDisease name (Link within this page)Number of trials
25Progressive multifocal leukoencephalopathy1
26HTLV-1-associated myelopathy1
28Systemic amyloidosis2
56Behcet disease1
96Crohn disease1

25. Progressive multifocal leukoencephalopathy


Clinical trials : 26Drugs : 35 - (DrugBank : 22) / Drug target genes : 8 - Drug target pathways : 37 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

26. HTLV-1-associated myelopathy


Clinical trials : 29Drugs : 47 - (DrugBank : 29) / Drug target genes : 34 - Drug target pathways : 119 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

28. Systemic amyloidosis


Clinical trials : 267Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

56. Behcet disease


Clinical trials : 81Drugs : 107 - (DrugBank : 30) / Drug target genes : 36 - Drug target pathways : 116 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

96. Crohn disease


Clinical trials : 2,442Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries